Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes
Inmaculada Peiró, Ramón Palmero, Pedro Iglesias et al. · Endocrine · 2019
Cited by 63 works. doi:10.1007/s12020-019-01871-7
Authors
- Inmaculada Peiró
- Ramón Palmero
- Pedro Iglesias
- Juan José Díez
- Andreu Simó-Servat
- Juan A. Marín‐Jiménez
- Laura Jiménez
- Eva Domingo‐Doménech
- Núria Mancho-Fora
- Ernest Nadal
- C Villabona
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Immortal Time Bias in Pharmacoepidemiology
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up